Newly-developed methods for estimation of in vivo binding to neurotransmitter receptors should enable the detection and quantification of physiologic or pathologic changes in receptor numbers. In the present study, both equilibrium and kinetic experimental strategies for in vivo muscarinic receptor determination were applied to the detection of receptor changes induced by chronic inhibition of acetylcholinesterase in the rat. Following one week of treatment, in vitro receptor autoradiography utilizing [3H]scopolamine revealed significant losses of muscarinic binding in the cerebral cortex, hippocampus, striatum and in cranial nerve motor nuclei. The in vivo distribution of [3H]scopolamine, following infusion to approach equilibrium binding in the brain, revealed reductions in binding which paralleled the pattern and magnitude of changes detected in vitro. A simplified tracer kinetic estimation following bolus injection of the ligand also detected substantial reductions in forebrain muscarinic receptor binding. These results indicate the feasibility of detecting receptor changes underlying neuropathologic conditions in vivo, and suggest that either equilibrium or kinetic experimental approaches may be extended to clinical research applications with the use of positron or single-photon emission tomography.
mography (PET) or single-photon emission computed tomography (SPECT), and may be employed for measurement of regional binding site densities with appropriate combinations of tracer molecules and experimental designs. As an example, prior research in experimental animals has indicated the feasibility of imaging muscarinic cholinergic receptor density on the basis of the distribution of [3H]scopolamine in vivo (2) (3) (4) .
Labeled scopolamine demonstrates desirable properties for in vivo studies including high specificity for binding to the muscarinic receptor, clear distinction of specific from nonspecific binding, and absence of labeled nonvolatile metabolites in the brain (2) . Volatile metabolites are observed in the brain following injection of [N-methyPH]scopolamine, presumably originating from peripheral metabolism of the tracer. However, they are easily removed by drying and do not interfere with accurate quantification of brain ligand distribution.
Two differing experimental protocols have each provided estimates of scopolamine binding in the intact rat brain. The first method employs equilibrium analysis following maintenance of a constant, saturating ligand concentration (2, 3) . This procedure results in a static regional distribution of ligand which corresponds to muscarinic receptor binding with minor contributions from the presence of nonspecific ligand binding and free ligand in the tissue. The second method makes use of kinetic compartmental analysis following bolus injection of a tracer dose of [3H]scopolamine (4) . In this instance, the time-courses of regional brain and arterial plasma tracer are required for estimation of receptor binding. These data may be collected at multiple time points from individual subjects with the use of PET. However, in experiments employing small animals, the data must be compiled from invasive measurements on groups of subjects killed at varying post-injection intervals. A simplified approach to kinetic binding estimation which requires independent knowledge or measurement of the regional cerebral capillary permeability-surface area product for the tracer and of regional cerebral blood flow has been previously proposed (4) . This method should allow binding estimates from a single observation of ligand distribution at a relatively long post-injection interval, when contribution from nonspecific binding is negligible.
An important aspect of development and evaluation of new radioligand methods is the ability to detect alterations in receptor binding which might arise in experimental applications. In the present studies, both the equilibrium and tracer kinetic experimental approaches to estimation of [3H]scopolamine binding are applied to measurements of receptor down-regulation following chronic inhibition of acetylcholinesterase.
EXPERIMENTAL PROCEDURE
Dntg Treatment. Chronic inhibition of acetylcholinesterase was achieved by daily i.m. injection of diisopropylfluorophosphate (DFP) suspended in olive oil. Male Sprague-Dawley rats weighing between 180 and 200 g were treated according to the following dose schedule: 1.5, 1.0, 1.0, 0.5, 0.5, and 0.5 Ixg DFP/kg on days 1 to 6 of treatment, respectively. Receptor binding experiments were performed 18 to 30 hr following the last treatment. Acute blockade of muscarinic receptors was produced by i.v. injection of atropine sulfate, 50 mg/kg, 5 min prior to in vivo binding studies.
Equilibrium Scopolamine Binding In Vivo. Equilibrium scopolamine binding to the muscarinic receptor in vivo was determined as described previously (2,3). The method employed results in equip ibration of cerebral receptors with a saturating (approximately 20 IxM) arterial plasma concentration of ligand, permitting regional estimates of receptor numbers from individual subjects. In brief, a bolus followed by a continuous infusion of [3H]seopolamine (15 mCi/kg total dose) were administered i.v. to produce a constant arterial concentration of tracer for 240 rain. At the.end Of the infusion, animals were killed and brains were frozen in crushed dry ice.
Coronal 20 izm thick sections were prepared in a cryostat and mounted on microscope slides, Sets of three slides, each containing duplicate sections, were obtained at intervals throughout the brain. The first of each group was rapidly dessicated on a hotplate at 60 to 70~ for determination of total in vivo binding. Sections on the subsequent two slides were thaw-mounted and allowed to dry at room temperature. One was used for determination of specific in vivo binding by washing in phosphate-buffered saline containing EDTA (PBS: NaC1 -124 raM, KC1 -2.7 raM, NazHPO 4 -7.7 mM, KHzPO 4 -1.5 raM, EDTA -1 mM, pH 7,4) at 4~ twice for 5 min, followed by a brief dip in 4~ distilled I420 to remove excess salts and air drying. This procedure had been shown to reduce nonspecific binding without loss of specific binding in preliminary in vitro binding assays to intact tissue sections. The final slide in each group was processed for in vitro determination of muscarinic receptors by pre-washing in PBS for 5 min, incubation in PBS containing a saturating concentration of [3H]sc0polamine (10 nM) for 30 min at 24~ followed by washing for 10 rain at 4~ and air drying.
AutoradiogramS were generated by apposing the slide-mounted tissue to tritium-sensitive X-ray film (Ultrofilm-aH, LKB, Gaithersburg, MD) for 14 days. Following film development, regional brain isotope concentrations were estimated by computer-assisted densitometry (MCID system, Imaging Research, St. Catherines, Ontario, Canada). Film densities overlying brain tissue were compared with those from calibrated radioactive standards, allowing estimation of apparent tissue radioactivity (5) . (1) where Cr and CA are the regional tissue and the arterial concentrations of ligand, f represents cerebral blood flow, PS represents the local cerebral capillary permeability-surface area product, and k3 represents the rate of ligand binding to the muscarinic receptor. The relationship between receptor availability and k3 is described by:
where k, is the bimolecular receptor-ligand association rate constant and R represents the free tissue receptor concentration. This simplified calculation of receptor binding following bolus administration of trace doses of [3H]scopolamine was applied in animals following chronic cholinesterase inhibition and following acute atropine treatment, the latter to verify the specificity of the simplified method to muscarinic receptor availability.
Femoral arterial and venous catheters were inserted in rats under light diethyl ether anesthesia. Following a 2 hr recovery period, binding studies were initiated by bolus i.v. injection of 100 ~Ci of [aH]scopolamine, and simultaneously beginning continuous arterial blood withdrawal into a heparinized 1 ml syringe at approximately 0.0067 ml rain -1 using an infusion/withdrawal pump (Harvard Apparatus, South Natick, MA). The possibility of ex vivo metabolism of the ligand in the blood sample was minimized by packing the withdrawal syringe in ice. At the end of a 90 rain distribution period, cerebral blood flow was determined by i.v. injection of 20 to 50 ~Ci of N,N,N',-trimethyl-N'-(2-hydroxy-3-methyl-5-[123I]iodobenzyl)-l,3-propanediamine ([123I]HIPDM) and simultaneous withdrawal of a second arterial blood sample at 0.21 ml rain -1 for 45 sec (6, 7) . Cardioplegia was then induced by i.v. injection of KC1, arterial sampling was discontinued, and animals were rapidly killed by decapitation.
Brains were dissected, and samples of the cerebral cortex, hippocampus, striatum and cerebellum were weighed on an analytical balance and dispersed by sonication in 1 ml of ethanol. Samples were then evaporated to dryness under vacuum to remove volatile JH, and were reconstituted by addition of 1OO ~i of HzO prior to the addition of 200 ~t of a tissue solubilizer (Soluene-350, Packard Instruments, Downers Grove, IL). The ~231 content of the samples was determined in a gamma counter within 24 hr of the study. Sample 3H contenl was determined one week later, after decay of the ~z~I (t~/z = 13.3 h), by addition of 1.8 ml of scintillation fluid (ACS, Amersham, Arlington Hts., IL) followed by liquid scintillation spectroscopy.
The integrated arterial concentration of [3H]scopolamine during the 90 rain distribution period was calculated from the volume of blood withdrawn (V), the time of withdrawal (,r), and the plasma concentration of authentic ligand in the sample:
where CA is the average concentration of unmetabolized [3H]scopolamine over the interval of observation, as may be determined from the continuously-acquired blood sample. The nonvolatile 3H plasma activity was determined by scintillation counting of duplicate 10 ~1 samples following drying at 60~ The fraction of nonvolatile activity corresponding to unmetabolized [3H]scopolamine was determined in parallel by thin-layer chromatography on silica gel with a tetrahydrofurandiisopropylethylamine 95:5 mobile phase (2). Regional cerebral blood flow was calculated from the tissue and second blood sample concentrations of [;z3I]HIPDM using the indicator fractionation method (8) as described by Van Uitert and Levy The regional scopolamine binding rate k~ was determined from the tissue [3H]scopolamine content, the integrated plasma pH]scopolamine concentration (eq 3), and regional cerebral blood flow (eq 4), according to eq 1. The cerebral PS for scopolamine was assumed to be 0.12 ml plasma/g brain/min as determined in prior studies (4) .
Materials. Labeled scopolamine was obtained by custom tritiation from Amersham (Arlington Hts., IL) and was adjusted to a specific activity of 30 Ci/mmol with unlabeled scopolamine.
Radioiodonated HIPDM was produced by exchange labeling (6) with the use of [a23I]NaI obtained from Crocker Laboratories (Davis, CA). Atropine sulfate, scopolamine hydrochloride, and DFP were purchased from Sigma (St. Louis, MO). 
RESULTS

Relationship of Equilibrium In Vivo Distribution to
Muscarinic Receptor Changes In Vilro Following
Chronic Acetylcholinesterase Inhibition. Following one week of acetylcholinesterase inhibition by DFP, regional brain muscarinic receptor binding was significantly reduced in several areas (Table I) . Most affected were the cerebral cortex, the hippocampal formation, the striaturn, the basolateral amygdala, and the nuclei of the facial and hypoglossal nerves. Other regions demonstrated only slight reduction or no change in binding with the exception of the substantia nigra pars reticulata, where a trend towards increased binding was observed. (Table II) were qualitatively similar to those in specific in vivo binding, following ex vivo washing of tissue sections (data not shown). The regional patterns and magnitudes of receptor changes were in good agreement between the equilibrium in vivo and the in vitro assays. :
Detection of Receptor Changes by Equilibrium In
Effects of Chronic AcetyIcholinesterase inhibition and of Acute Atropine Treatment on Kinetic Receptor
Binding Estimates. Regional cerebral blood flow was decreased approximately 15 to 35% by chronic administration of DFP in all regions examined (~able III). Reductions in the k3 estimates for [3H]scopo!amine of approximately 50% were observed in the cerebral cortex, striatum, and hippocampus (Table IV) . In the cerebelIum, kinetic binding estimates were reduced by comparison to controls, however, the magnitude of the change was minor by comparison to the forebrain regions. Cerebral cortical kinetic binding estimates expressed relative to the cerebellum reveal substantial reductions following DFP treatment, suggesting a differentially In Vitro Binding, dpm//xg protein greater effect on the forebrain regions than on cerebellar binding.
Acute administration of a saturating dose of atropine resulted in small increases in CBF and large reductions in muscarinic receptor binding estimates, the latter ranging between 90 to 95% in the forebrain regions and over 75% in the cerebellum. Thus, most of the kineti- cally-estimated ligand binding in the control and DFPtreated groups is attributable to muscarinic receptor availability.
Frey, Ciliax, and Agranoff
DISCUSSION
Relationship of In Vivo and In Vitro Equilibrium Receptor
Binding. The present study extends prior observations on the equilibrium binding application of labeled scopolamine for measurement of cerebral muscarinic receptor availability in vivo. It has been previously determined that the relationship between total scopolamine binding in vivo and in vitro estimates of muscarinic receptors made with [3H]quinuclidinyl benzilate are highly correlated, and that there is a component suggestive of the presence of nonspecific binding and free ligand under in vivo conditions (2, 3) . In the present studies, this speculation has been confirmed following ex vivo washing of tissue to reduce the contribution of nonspecific binding. Following washing, the relationship between in vivo and in vitro binding is linear with an intercept at the origin.
An unexpected additional finding in these studies is the apparent increase in ligand concentration following washing of the tissue, particularly evident in brain regions with greatest receptor densities. Several of these regions appear to deviate from the linear relationship between total binding in vivo and in vitro determined for regions of low to moderate receptor concentration. The apparent underestimation of in vivo binding in these regions is not due to failure to fully equilibrate ligand binding, the presence of endogenous neurotransmitter, or other factors affecting the biodistribution of tracer, since post-washing of the labeled tissue restores linear correlation of the in vivo and in vitro binding estimates in these regions. It is unlikely that unbound tracer from distant regions is removed and then rebound to account for these changes, since the washing procedure was conducted in relatively large volumes of buffer (greater than 10 ml per slide in each of two 5 rain washes) and was conducted at 4~ An alternative is suggested by inspection of the linear regression slopes in the pre-and post-washing conditions. An increase in the slope relating in vivo to in vitro binding is seen even in the regions of low receptor concentration. In addition, the regression slope in the in vivo specific binding case is less than unity, suggesting that incubation of tissue for 30 min at 24~ produces an incremental effect. These observations suggest that incubation in buffer alters the self-absorption properties of the tissue sections, perhaps by elimination of salts, soluble proteins, or other attenuating factors. The differential effects noted in the cerebral cortex and hippocampal formation may be due to concentration of binding sites in subregions (lamina) with greatest loss of attenuating factors. Tissue attenuation effects on autoradiographic quantification of tritium have been previously documented in relation to regional differences in brain lipid content (10) (11) (12) . The effect suggested by the present studies cannot be investigated in exclusively in (15) found reductions in cerebral cortical, striatal, and hippocampal binding as in the present work. The prior results, however, suggest reductions in septal and pontine binding not evident in the present study. The reduction in hypoglossal nucleus and the small increase in substantia nigra receptor binding observed in the present work have not been previously reported. The reason for these discrepancies is uncertain, but may reside in differences in DFP administration schedules or in the methodology for quantification of autoradiographic binding. Nevertheless, the major findings of the investigations are in agreement that DFP treatment produces a loss of muscarinic receptor binding in forebrain areas with high densities of presynaptic cholinergic terminals. It is likely that this effect is indirectly mediated by increases in acetylcholine levels, since prior lesioning of presynaptic cholinergic terminals prevents neocortical receptor losses (14) .
Comparison of Equilibrium and Tracer Kinetic
Binding Methods. Results from both equilibrium and kinetic in vivo binding studies indicate the feasibility of detecting altered receptor populations. By comparison with the results of in vitro binding, neither in vivo method appears as sensitive, due to variability in the data. The equilibrium method results in better precision than the kinetic method, however, this may be partly attributed to differences in region identification and tissue sampling which tend to favor the autoradiographic equilibrium binding design. In addition, the kinetic calculation applied here may suffer from invalid assumptions concerning ligand transport. First, the determination of cerebral blood flow was made at the end of the 90 min [3H]scopolamine distribution period. Since effects of flow on ligand transport and binding are greatest immediately following bolus injection, changes in perfusion during the course of the experiment might lead to inaccurate correction for ligand transport. Second, and more significantly, since scopolamine transport is highly sensitive to PS, it may be incorrect to assume a constant value across experimental groups. A combination of these errors may underlie apparent loss of binding in the cerebellum in kinetic studies. It has been previously reported that PS varies in the same direction as cerebral blood flow during alterations in arterial pCOz and following administration of antidepressants (16) (17) (18) . Thus, PS may have been lower than assumed in the DFP-treated animals, leading to underestimation of binding in the kinetic experiments. This error alone may be sufficient to account for the small reduction in cerebellar binding, and may contribute to the greater magnitude of forebrain receptor losses in the kinetic as compared to the equilibrium experiments. On the basis of method precision and due to the considerations above, the equilibrium in vivo [3H]scopolamine binding method would appear most favorable for studies in experimental animals.
Implications for Clinical Receptor Imaging Studies.
Clinical research quantification of muscarinic receptors may, in theory, be accomplished by application of PET imaging to the detection of scopolamine labeled with the positron emitting nuclide 11C ([11C]scopolamine; 19, 20) . On the basis of the foregoing comparison in experimental animals, the equilibrium approach might appear desirable for clinical measures as well. However, equilibrium imaging with labeled scopolamine requires saturating ligand levels over a several hour period. Both of these conditions are unobtainable due to the adverse clinical effects of high doses of scopolamine and to the short (20 min) isotopic half-life of 11C. The tracer kinetic experimental design is thus the only available choice for such studies, and might yield results more precise than predicted by the current studies. The entire brain time-course of tracer activity may be obtained by dynamic PET imaging, eliminating the need for simplifying assumptions about initial ligand extraction, PS, and CBF. Thus, the physiologic accuracy and precision of clinical kinetic measures may exceed estimates derived from the current animal studies. In fact, measurements of muscarinic receptor binding with the kinetic [l~C]scopolamine method have been achieved with PET in normal human volunteers (21) . The present studies suggest the feasibility of detecting alterations in cortical and perhaps other regional receptor populations with this method. 
